ADC Therapeutics SA reported third‑quarter 2025 results that showed revenue of $15.8 million, a 12% decline from the $18.0 million earned in the same period last year. The company posted a net loss of $41.0 million, or $0.30 per share, compared with a $44.0 million loss ($0.42 per share) in Q3 2024. While revenue fell short of the consensus estimate of $16.1 million, the earnings per share beat the $‑0.40 expectation by $0.10, reflecting tighter cost control amid a modest decline in product sales.
The revenue drop was driven primarily by a 12% decline in product sales, as demand for the early‑line ZYNLONTA therapy slowed in the quarter. However, the company’s pipeline remains robust: data from the LOTIS‑7 trial are expected by year‑end 2025, and the Phase 2 investigator‑initiated study of ZYNLONTA plus rituximab in follicular lymphoma reported an overall response rate of 98.2% and a complete response rate of 83.6%. These results suggest that future revenue growth will likely accelerate once the company expands ZYNLONTA into earlier lines of therapy for diffuse large B‑cell lymphoma and indolent lymphomas.
The net loss narrowed from the prior year, largely because R&D and SG&A expenses were kept in check even as the company invested heavily in its pipeline. Management emphasized that the company’s cost discipline has improved, allowing it to absorb the higher research spend without widening the loss margin as much as in 2024.
In addition to the earnings, ADC Therapeutics completed a $60 million private investment in public equity (PIPE) financing, netting approximately $57.6 million in proceeds. The transaction lifts the company’s cash runway to roughly $292.3 million and provides the resources needed to accelerate the commercial rollout of ZYNLONTA. CEO Ameet Mallik said the financing “strengthens the balance sheet and provides resources to further invest in ZYNLONTA, anticipating advancements into earlier lines of therapy for DLBCL and into indolent lymphomas.”
Management maintained its guidance for the remainder of the year, indicating continued investment in the pipeline while keeping revenue and earnings outlooks unchanged. Analysts remain upbeat, citing the strong financing position and promising clinical data as key drivers of future growth potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.